- Randomized, triple-blinded, placebo-controlled two-centre trial of 80 adults undergoing primary breast cancer surgery, with or without axillary dissection.
- Patients received either an ultrasound-guided erector spinae plane block (n=40) or intraoperative IV lidocaine infusion (n=40), both within a standardized multimodal analgesic protocol.
- The 24-hour QoR15 score was 137.7 (SD 17.9) with ESPB versus 136.3 (SD 8.8) with IVLI, p=0.61.
- Pain scores, opioid use and rescue analgesia were similarly low in both groups, and the authors suggest IVLI may be a pragmatic option when regional expertise is limited.
Pharmacology
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- This PRISMA-ScR scoping review screened 2,187 records and included 12 studies of ketamine with pain and depression outcomes assessed longitudinally.
- Eight studies enrolled chronic pain patients and four enrolled depression-primary populations, while acute, perioperative, perinatal, and cancer-related pain were excluded.
- Most studies reported concurrent improvement in pain and depressive symptoms, but the abstract gives no pooled effect size.
- The authors conclude that heterogeneity in populations, dosing, design, and comorbidity prevents inferring that depression modifies ketamine's analgesic effect, and call for randomized trials.
AI summary not available. Read the source abstract on PubMed.
AI summary not available. Read the source abstract on PubMed.
- Systematic review and meta-analysis of 165 randomised trials, including 19,124 adults receiving rocuronium or vecuronium for elective procedures.
- Sugammadex 2 mg/kg was compared with neostigmine 0.05 mg/kg for neuromuscular blockade reversal, though risk of bias across trials was generally unclear or high.
- Sugammadex shortened time to a train-of-four ratio above 0.9 by 10.49 minutes (95% CI -11.90 to -9.08; moderate GRADE) and lowered the risk of at least one adverse event (RR 0.72, 95% CI 0.61 to 0.84).
- The authors conclude sugammadex probably reverses blockade faster with fewer adverse events, including residual blockade, desaturation and bradycardia, though the evidence is rated moderate certainty.
- Meta-analysis of 22 RCTs including 4161 older surgical patients under general anesthesia, searched across PubMed, Embase and CENTRAL through July 2026.
- Compared perioperative intravenous dexmedetomidine with control for prevention of postoperative delirium, the primary outcome.
- Dexmedetomidine reduced postoperative delirium (RR 0.56, 95% CI 0.47 to 0.66; P<0.00001; I² 24%) and PONV (RR 0.79, 95% CI 0.62 to 0.99; P=0.04).
- Dexmedetomidine was associated with more intraoperative and postoperative bradycardia and more intraoperative hypotension.
AI summary not available. Read the source abstract on PubMed.
- Single-centre, double-blind randomised noninferiority trial of 686 adults having elective neurovascular surgery, analysed as a modified intention-to-treat population.
- Patients received remimazolam-based TIVA with flumazenil reversal at emergence or propofol-based TIVA, both with remifentanil.
- Postoperative delirium within 5 days occurred in 12.8% (44/344) with remimazolam and 10.8% (37/342) with propofol; risk difference 1.97 percentage points (95% CI -2.85 to 6.80).
- Remimazolam met the prespecified noninferiority criterion, and that group had less intraoperative hypotension below a MAP of 65 mm Hg and more operating-room extubation.
- Systematic review and meta-analysis of five randomized trials, totaling 1613 adults aged 60 or older having surgery under regional anesthesia.
- Compared intraoperative dexmedetomidine with propofol, with delirium assessed using CAM or CAM-ICU.
- Delirium occurred in 7.7% of dexmedetomidine patients versus 16.7% with propofol (RR 0.48, 95% CI 0.36-0.64; P < .001), with low heterogeneity (I² = 13.4%).
- The authors conclude dexmedetomidine is associated with less postoperative delirium, and they rated the certainty of evidence as moderate by GRADE.
- Randomized, double-blind, placebo-controlled single-center trial of 70 patients undergoing on-pump CABG.
- Patients received intranasal dexmedetomidine 1 μg/kg or saline on the night before surgery and again 30 minutes before induction.
- At 24 hours, estimated marginal mean hs-cTnT was 170.29 vs 357.29 ng/L (P < 0.001) favoring dexmedetomidine; CK-MB was also lower.
- Sleep quality scores were higher and postoperative delirium was lower (14.3% vs 37.1%; P = 0.029), but the authors call the findings preliminary.
AI summary not available. Read the source abstract on PubMed.
- Randomized block study in adult Sprague Dawley rats using viral constructs to express channelrhodopsin or a control protein in tyrosine hydroxylase-positive VTA neurons.
- Optogenetic stimulation of these neurons was tested during sevoflurane, dexmedetomidine, fentanyl, and ketamine unconsciousness, with and without light.
- Photostimulation restored sevoflurane-anesthetized righting at a median 4.7 min (95% CI, 2.6 to 6.4); after dexmedetomidine, hazard ratio 27.7 (95% CI, 2.7 to 287.1; P = 0.0053).
- Effects were agent specific: no change after fentanyl, a modest delay in ketamine emergence, and the authors suggest distinct and sometimes opposing pathways shape the role.
- Single-center retrospective before-and-after cohort with propensity matching in a cardiothoracic ICU compared 122 ketamine and 122 control patients after cardiac surgery.
- Patients on an ERAS pathway received a continuous low-dose ketamine infusion (0.1-0.3 mg/kg/h) or no ketamine as the control.
- Cumulative opioid use over POD0-2 was lower with ketamine (30 vs 52.5 MME; p = 0.003), and time to first analgesic was longer (7.4 vs 4.5 h; p < 0.001).
- No hallucinations were seen and urinary retention fell (9.8% vs 34%; p < 0.001), and the authors describe ketamine as a safe adjunct.
- This mini review synthesizes a targeted search of pediatric esketamine studies covering analgesia, sedation, propofol injection pain, and emergence delirium or agitation.
- Randomized trials and meta-analyses generally report fewer emergence delirium or agitation events after low intravenous esketamine doses, mostly during sevoflurane adenotonsillectomy.
- Direct dose-comparison evidence in that setting shows increasing benefit up to 0.5 mg/kg intravenously, with no upper efficacy or safety boundary identified.
- The authors conclude that 0.2-0.5 mg/kg IV was the best-studied range for emergence prevention, not a validated therapeutic window, and call for direct dose-timing trials.
- Randomised, quadruple-blind trial of 90 patients aged 65-100 undergoing primary total knee arthroplasty, comparing dexamethasone adjuncts to adductor canal and iPACK blocks.
- Perineural dexamethasone (4 mg total, 2 mg per block) with ropivacaine was compared with intravenous dexamethasone 4 mg and with placebo.
- Median time to first rescue opioid was 4.5 h with placebo, 13.9 h with IV dexamethasone and 18.5 h with perineural dexamethasone (log-rank p < 0.001).
- Perineural dexamethasone produced lower opioid use than IV at later timepoints, and no motor weakness or nerve injury was reported.
- Meta-analysis of 25 randomized controlled trials (3344 patients) comparing perioperative ketamine or esketamine with placebo or standard care for postoperative delirium.
- Ketamine (9 trials) and esketamine (16 trials) were compared with control, with subgroup analyses by dose, regimen, surgery type and timing of assessment.
- Both agents reduced postoperative delirium risk: ketamine RR 0.69 (95% CI 0.49-0.98, P = .04) and esketamine RR 0.58 (95% CI 0.36-0.95, P = .03).
- Dizziness risk rose (RR 1.45, 95% CI 1.14-1.84), and trial sequential analysis found the evidence inconclusive, so the authors call for large multicenter RCTs.
AI summary not available. Read the source abstract on PubMed.
- Systematic review and meta-analysis of 14 reports of randomized trials (1,773 participants in the primary synthesis), all conducted in China, in adults undergoing cardiac surgery.
- Compared remimazolam-based with propofol-based general anesthesia for induction and maintenance.
- Remimazolam was associated with fewer trial-defined intraoperative hypotension (OR 0.31; 95% CI 0.20-0.47) and bradycardia events (OR 0.20; 95% CI 0.12-0.34), and shorter mechanical ventilation (MD -1.84 hours; 95% CI -2.34 to -1.35).
- Length of stay did not reach significance (MD -0.48 days; 95% CI -0.99 to 0.02; p = 0.06), major morbidity and mortality could not be pooled, and certainty was very low.
- Pharmacokinetic study of term laboring women, with 10 receiving calcium carbonate and 8 receiving calcium citrate.
- Participants took oral calcium carbonate 1200 mg, and the protocol was later amended to calcium citrate 1250 mg after an interim analysis.
- Serum ionized calcium showed minimal to no increase after either formulation, with no effect sizes or p values reported.
- The authors conclude the package-insert dose did not meaningfully raise ionized calcium and that future work should focus on intravenous calcium.
- Randomized controlled trial of 68 breast cancer patients (34 per arm) undergoing quadrantectomy, comparing opioid-free general anesthesia with locoregional blocks against opioid-based general anesthesia.
- The primary endpoint was the neutrophil-to-lymphocyte ratio (NLR), measured before surgery and at 1 and 24 hours after; secondary endpoints included side effects, pain management, and inflammatory cytokines.
- In the opioid-based arm, NLR rose from baseline at 1 hour (median change +0.13, IQR 0.01 to 0.62, p<0.0001) and 24 hours (+0.64, IQR 0.28 to 1.03, p<0.0001), while the opioid-free arm showed no significant change.
- The authors conclude that opioid-free anesthesia was associated with a reduced postoperative inflammatory response without compromising pain control, and it was better tolerated with fewer side effects.
- Randomized controlled trial of 60 children undergoing adenotonsillar surgery, allocated to methylprednisolone, dexamethasone, or no corticosteroid.
- Children received methylprednisolone 1 mg/kg, dexamethasone 0.2 mg/kg, or no steroid before sugammadex reversal of rocuronium block.
- Reversal time was longer with methylprednisolone (82.8 ± 16.1 s) than with dexamethasone (63.4 ± 13.4 s) or control (56.1 ± 13.7 s), p < 0.001.
- Extubation time followed a similar pattern, while postoperative pain, nausea, and adverse event rates did not differ significantly between groups.
- This delirium-focused secondary analysis of a single-centre, double-blind, placebo-controlled trial enrolled adults having head and neck cancer surgery with free-flap reconstruction.
- Patients received intraoperative dexmedetomidine at 0.3 μg/kg/h until 1 hour before surgery ended, or comparable volumes of saline placebo.
- Delirium over the first 5 postoperative days occurred in 14.9% (7/47) of dexmedetomidine patients versus 34.7% (17/49) of placebo patients (adjusted OR 0.31, 95% CI 0.10-0.92; p = 0.036).
- Pain and early sleep were reported as improved with dexmedetomidine, and haemodynamic adverse events and postoperative complications did not differ significantly between groups.
- Systematic review and network meta-analysis of 24 RCTs (22 in the meta-analysis, 2,544 patients) in adults admitted to the ICU after non-cardiac surgery.
- Compared dexmedetomidine with normal saline, midazolam, and propofol as postoperative sedation strategies, with ICU delirium as the primary outcome.
- Dexmedetomidine may reduce delirium versus midazolam (RR 0.11, 95% CI 0.02 to 0.80; very low certainty) and versus normal saline (RR 0.46, 95% CI 0.36 to 0.59; low certainty).
- No differences in extubation time or ICU length of stay across strategies, while bradycardia was probably more likely than with propofol (RR 3.03, 95% CI 1.39-6.25; low certainty).
- In vitro study using human iPSC-derived cortical-ganglionic eminence assembloids, characterised by immunohistochemistry and single-nucleus RNA sequencing.
- Assembloids were exposed to 96 μM propofol and compared with excitatory cortical-only organoids and with propofol plus the GABAA antagonist bicuculline.
- Propofol increased relative delta power (P=0.0078), reduced local field potential complexity (P=0.0117), and suppressed neuronal firing (P=0.0156); effects were absent in cortical-only organoids and abolished by bicuculline.
- The authors conclude that a minimal cortical circuit with functional GABAA receptors is sufficient for these anaesthetic-induced changes and propose the model for mechanistic and drug-screening work.
- Retrospective single-centre cohort of 341,199 adults receiving propofol sedation or volatile general anaesthesia at Beth Israel Deaconess, Boston, 2008–2024.
- Exposure was cannabis use, split into medical certification versus non-medical use (recreational use or cannabis use disorder).
- Non-medical cannabis use was associated with a 6.85 μg/kg/min higher propofol dose (95% CI 6.07–7.63, P<0.001), and medical use with 2.87 μg/kg/min higher (95% CI 0.88–4.86, P=0.005).
- Volatile anaesthetic increases were small (0.01 and 0.02 MAC), and the authors concluded effect sizes were smaller than previously reported, with clinical relevance still unclear.
AI summary not available. Read the source abstract on PubMed.
- Propensity-matched retrospective cohort using TriNetX electronic health records of adults undergoing lumbar spine surgery from 2010 to 2024, with 53,639 opioid-naive and 2031 OUD patients analyzed.
- Exposure was intraoperative ketamine, analyzed separately in opioid-naive patients and those with opioid-use disorder.
- Ketamine was linked to more outpatient opioid prescribing in opioid-naive patients at 48 hours (RR 1.23, 95% CI 1.22-1.25) and 6 weeks (RR 1.14, 95% CI 1.10-1.18).
- Adverse events and new OUD diagnoses were not reduced and were similar or higher with ketamine, so the authors found no detectable population-level opioid-sparing signal.
- Single-centre prospective observational study of intraoperative data from 20 adult female patients undergoing breast surgery during stable propofol-remifentanil anaesthesia.
- Lidocaine was given as a 1.5 mg/kg i.v. bolus over 10 min, followed by a 30 min infusion at 1.5 mg/kg/h, and EEG, BIS, SEF95 and SPI were tracked.
- Delta-band EEG activity increased and beta-band activity decreased 4 to 6 min after the bolus, while BIS and SEF95 did not change significantly at that time.
- BIS, SEF95 and SPI decreased later in the infusion phase, and the authors conclude that EEG changes precede BIS, SEF95 and SPI changes, consistent with an antinociceptive contribution.
- Pragmatic, open-label, multicenter randomized trial of 2508 adults aged 50 or older having elective major noncardiac surgery at 49 UK NHS hospitals.
- Patients were randomized 1:1 to maintenance of general anesthesia with propofol TIVA or volatile inhalational agents, with other perioperative care left to clinician discretion.
- Days alive and at home at 30 days were similar (22.5 vs 22.4 days; incidence rate ratio 1.00, 95% CI 0.99-1.02; adjusted P = .68).
- TIVA was associated with lower reported thirst, hoarseness, and nausea/vomiting; major complications (12.4% overall) did not differ between groups.
- A retrospective, single-center, propensity-matched cohort of 264 TAVI patients under monitored anesthesia care, 132 per group, was analyzed.
- Remimazolam-based sedation was compared with dexmedetomidine-based sedation for intraprocedural hemodynamic instability.
- Hemodynamic instability was less frequent with remimazolam (53.8% vs. 69.7%; adjusted OR 0.50, 95% CI 0.31-0.82; P = 0.006), driven mainly by fewer vasoactive treatments for hypotension.
- Rescue midazolam use was much lower with remimazolam (1.5% vs. 43.2%), while respiratory events, conversion to general anesthesia, delirium, and 30-day outcomes did not differ.
- This preclinical mouse study tested post-anesthetic feeding after propofol across several doses, hunger states, and day and night phases.
- Propofol at an anesthetic dose of 100 mg/kg was compared with subanesthetic doses, and PVN GLP-1R neurons were optogenetically activated or inhibited during recovery.
- Anesthetic-dose propofol suppressed food intake regardless of circadian phase or metabolic state, and propofol abolished the normal drop in these neurons' activity during feeding.
- Activating these neurons suppressed feeding and inhibiting them increased it during recovery, and the authors conclude that they are essential mediators of propofol-induced feeding suppression.
- Single-center randomized non-inferiority trial in China with 316 randomized elderly patients (of 535 screened) undergoing elective unilateral total knee or hip arthroplasty.
- Intranasal dexmedetomidine the night before surgery plus IV saline at induction was compared with intranasal saline plus IV dexmedetomidine before induction.
- Delirium within 3 days by CAM occurred in 9.5% vs 7.6%; rate difference 0.02 (95% CI -0.04 to 0.08), reported P<0.001, meeting non-inferiority.
- Authors also reported better sleep the night before surgery, lower preoperative anxiety and pain scores, and fewer adverse events with the intranasal route.
- Double-blinded randomized trial of 100 women after cesarean delivery (95 completed), comparing dexamethasone 8 mg with ondansetron 4 mg.
- Both groups received spinal anesthesia with morphine 150 µg and an enhanced recovery protocol with scheduled nonopioid analgesics; the main outcome was rescue medications for nausea, vomiting, pain, or pruritus over 24 hours.
- Medication use did not differ significantly: ondansetron 0.23 (95% CI 0.11-0.35) versus dexamethasone 0.40 (0.20-0.61) per patient per 24 hours; P = .337.
- Supplemental pain medication, pain scores, nausea, and pruritus scores also showed no significant differences. The authors suggest low pain scores and breakthrough pain rates may explain the lack of pain benefit seen in prior dexamethasone studies.
- Double-blind randomized placebo-controlled trial in 120 mechanically ventilated adults on opioid infusion at two Melbourne ICUs, excluding cardiac surgical patients.
- Patients received low-dose ketamine infusion (0.15 mg/kg/hr) or placebo during mechanical ventilation.
- Median hourly opioid dose was 64 µg/hr with ketamine versus 77 µg/hr with placebo (median difference -13.0, 95% credible interval -26.6 to 2.4; probability of benefit 95.1%).
- Authors concluded low-dose ketamine appeared safe and reduced opioid requirements, while noting that delirium and most other secondary outcomes did not differ and larger trials are needed.
- Prospective single-blind diagnostic study of 74 children sedated with chloral hydrate and dexmedetomidine for MRI at a tertiary hospital.
- The EEG-derived wavelet index (WLI) was compared with the Ramsay Sedation Score (RS) for predicting MRI sedation failure, with scanning started once RS reached 5 or 6.
- WLI had an AUC of 0.902 (95% CI 0.814-0.990) versus 0.734 (95% CI 0.603-0.876) for RS, a paired ΔAUC of 0.162 (95% CI 0.004-0.329; p = 0.038), and nine of 74 children failed sedation.
- The authors suggest WLI may serve as an adjunctive, non-stimulating tool for risk stratification, while noting that clinical utility of WLI-guided management needs prospective confirmation.
- Pharmacokinetic study in 44 adult volunteers across obesity levels, 30 (68.2%) with obstructive sleep apnoea, using stepwise remimazolam infusion and arterial sampling.
- Remimazolam and its metabolite CNS7054 were modelled jointly, with a three-compartment model fitting remimazolam best and a one-compartment model with transit compartment fitting the metabolite.
- Clearance was 1.09 l/min (RSE 4%), and total body weight, but not sleep apnoea severity, significantly affected clearance and metabolite volume of distribution.
- In class 2/3 obesity, context-sensitive half-time after a 4-h infusion was 4.02 min, and lean or adjusted weight dosing gave profiles comparable with total weight dosing in normal weight patients.
AI summary not available. Read the source abstract on PubMed.
- Systematic review and meta-analysis of 12 randomised trials (n = 739) comparing remimazolam with sevoflurane for general anaesthesia maintenance or deep sedation.
- Remimazolam was compared with sevoflurane, with outcomes covering intraoperative haemodynamic stability and postoperative nausea and vomiting.
- Remimazolam reduced the risk of intraoperative hypotension versus sevoflurane, RR 0.38 (95% CI 0.25 to 0.57; P < 0.001).
- MAP and heart rate differences appeared only at specific time points, and the PONV reduction came from sensitivity analyses, not the primary analysis.
- Randomized, participant- and assessor-blinded trial of 94 patients undergoing primary unilateral total knee arthroplasty.
- Compared a single-injection adductor canal block with perineural dexamethasone against the same block followed by a continuous adductor canal catheter infusing 0.2% ropivacaine for 50 hours.
- No significant difference in opioid use at 24-48 hours (median 30 mg vs 38.8 mg; 95% CI -22.50 to 7.00 mg; p=0.213), and PACU opioid use was also not significantly different (p=0.081).
- Catheter-associated buckling occurred in 7% of the continuous group versus 0% of the single-injection group, all transient; the authors concluded the catheter did not reduce opioid use.
- Randomized dose-finding trial using a Dixon up-and-down design in 50 children aged 2 to 14 years having elective surgery.
- Children received a single intravenous bolus of remimazolam or propofol for induction, in two parallel dose-finding arms.
- Remimazolam's ED50 for loss of consciousness was 0.17 mg/kg (95% CI 0.16-0.19) and its ED95 was 0.26 mg/kg (95% CI 0.23-0.29).
- Heart rate was more stable with remimazolam, and no respiratory depression or hypotension occurred in either group.